Nama's AI scorecard currently rates Silence Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does SLN report earnings?

Silence Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.09.

What is the SLN price target?

The median analyst price target from 4 analysts is $20.00, with a range of $19.00 – $20.00.

Is SLN Shariah compliant?

Nama's AAOIFI-style screen reads Silence Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Silence Therapeutics (SLN)

Healthcare · Biotechnology · NASDAQ

Silence Therapeutics (SLN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.23B and a free-cash-flow yield of -6.7%. Over the most recent reported fiscal year, revenue declined 98.7%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 6, 2026.

Momentum

Middle · +52.2% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-28.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.23B
Trailing P/E	—
Price / book	73.1
Price / sales	1973.0
FCF yield	-6.7%
Dividend yield	—
Gross margin	85.8%
Operating margin	-11106.8%
Net margin	-9748.5%
Revenue growth (YoY)	-98.7%
Revenue growth (3-yr annual)	-70.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

SLN earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.09). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	-$0.27	-$0.11	-145.4%	$0
Q1 2026	May 7, 2026	-$0.33	-$0.09	-266.7%	$422,000
Q4 2025	Mar 5, 2026	-$0.27	-$0.49	+44.9%	$34,000
Q3 2025	Nov 6, 2025	-$0.15	-$0.21	+28.6%	$159,000

SLN analyst price target

Median target $20.00 from 4 analysts, ranging $19.00 – $20.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live SLN data on Nama Insights →

SLN FAQ

Is SLN a buy?: Nama's AI scorecard currently rates Silence Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SLN report earnings?: Silence Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.09.
What is the SLN price target?: The median analyst price target from 4 analysts is $20.00, with a range of $19.00 – $20.00.
Is SLN Shariah compliant?: Nama's AAOIFI-style screen reads Silence Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.